Advances in the Inhibitors of Janus Kinase

In recent years, for the lesion site, studies at the molecular level of drugs targeting protein molecules has been a major research method for exploiting new, high-efficiency drugs with low toxicity [1]. Janus kinases (JAKs) are important signal transducers of many cytokines, growth factors and interferon. In recent years, it has been found in cancer cells and cells transfected with oncogenes that there would be a significant enhancement in the expression of JAKs. Also, the expression of JAKs has a close relationship with inflammation and autoimmune diseases and immune rejection of the allograft following formation [2]. With the research development of JAKs, a large number of safe, high-efficiency and highly selective JAKs inhibitors have been designed, which can selectively block JAKs signal transduction systems. According to clinical trial results, JAKs have high selectivity, high bioavailability, therapeutic activity and are well tolerated, which makes the treatment of diseases using JAKs possible [3].